Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A reminder that clients applicable (100+) will be required to complete specific Instruction to Release (ITR) documentation that authorizes Highmark to extend access to this utility
Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)
A proprietary black cumin oil extract (Nigella sativa) (BlaQmax((R))) modulates stress-sleep-immunity axis safely: Randomized double-blind placebo-controlled study
Significant Weight Reduction: Clinical studies reveal that Semaglutide, combined with healthy lifestyle changes, can help lose up to 15% of their body weight
US$ 29.27
US$ 20.15
US$ 28.45
US$ 25.26
